Form 8-K

8-K — Silexion Therapeutics Corp

Accession: 0001178913-26-003796

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0002022416

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — zk2635818.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (exhibit_99-1.htm)

GRAPHIC (image_001.jpg)

GRAPHIC (image_002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: zk2635818.htm · Sequence: 1

false

0002022416

00-0000000

0002022416

2026-04-28

0002022416

us-gaap:CommonStockMember

2026-04-28

0002022416

SLXN:WarrantsExercisableForOrdinarySharesMember

2026-04-28

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

August 4, 2026

Silexion Therapeutics

Corp

(Exact name of registrant as specified in its charter)

Cayman Islands

001-42253

N/A

(State or other jurisdiction

(Commission File Number)

(I.R.S. Employer

of incorporation)

Identification No.)

12 Abba Hillel Road

Ramat-Gan, Israel

5250606

(Address of principal executive offices)

(Zip Code)

+972-3-756-4999

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously

satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on

which registered

Ordinary Shares, par value $0.135 per share

SLXN

The Nasdaq Stock Market LLC

Warrants exercisable for Ordinary Shares at an exercise price of $15,525.00 per share

SLXNW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 4, 2026, Silexion Therapeutics Corp

issued a press release entitled “Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism

Immune Sensitization by SIL204 in KRAS-Driven Cancers”. A copy of the press release is furnished as Exhibit 99.1 to this Current

Report on Form 8-K (this “Form 8-K”) and is incorporated herein by reference.

The information in this Item 7.01 of Form 8-K,

including the information in the press release furnished pursuant to this Item 7.01, shall not be deemed “filed” for the purposes

of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore,

the information in this Item 7.01, including the information in the press release, shall not be deemed to be incorporated by reference

in the filings of the registrant under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1

Press Release dated August 4, 2026

104

Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SILEXION THERAPEUTICS CORP

Date: August 4, 2026

/s/ Ilan Hadar

Name:

Ilan Hadar

Title:

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: exhibit_99-1.htm · Sequence: 2

Exhibit 99.1

Silexion Therapeutics

Reports New Positive Preclinical Findings Demonstrating Multi-

Mechanism Immune

Sensitization by SIL204 in KRAS-Driven Cancers

New preclinical data demonstrate that SIL204

treatment produced statistically significant upregulation

of FAS (CD95), the immune “death receptor,” and statistically significant

downregulation of HLA-G, an

established immune checkpoint, in human KRAS-mutant pancreatic and non-small cell lung cancer cell

lines representing

three distinct KRAS mutations (G12D, G12V, and G12C)

Combined with previously reported MHC-I upregulation,

findings support a coordinated immune-

sensitization signature across three key immune pathways - increased antigen presentation, restored

susceptibility to immune-mediated apoptosis, and reduced immune checkpoint activity - and reinforce

the scientific rationale for combining

SIL204 with anti-PD-(L)1 immune checkpoint inhibitor therapies

Findings emerge as Silexion advances SIL204

into Phase 2/3 clinical evaluation, following successful

initiation of the Company’s first clinical trial site at Tel Aviv Sourasky

Medical Center at the end of July

2026

Grand Cayman, Cayman Islands, August 4, 2026 -- Silexion Therapeutics

Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference

(RNAi) therapies for KRAS-driven cancers, today announced additional positive preclinical findings from its ongoing translational immuno-oncology

program evaluating SIL204 in human KRAS-mutant cancer cells. The new findings further expand SIL204’s therapeutic profile by demonstrating

a coordinated immune-sensitizing effect on tumor cells, reinforcing the scientific rationale for combining SIL204 with anti-PD-(L)1 checkpoint

inhibitor therapies. In newly reported studies performed across three human cancer cell lines representing three different KRAS mutations,

SIL204 treatment produced statistically significant increases in expression of FAS, a well-established immune “death receptor,”

and statistically significant reductions in expression of HLA-G, an immune checkpoint that tumors use to evade immune surveillance. The

findings, generated in human pancreatic (KRAS G12D) and non-small cell lung cancer (NSCLC; KRAS G12V and G12C) cell lines, build on the

Company’s previously reported MHC-I upregulation data announced in May 2026, and further support SIL204’s potential to act

as a multi-mechanism immune sensitizer in KRAS-driven tumors.

“These new findings meaningfully extend and reinforce the immuno-oncology

profile of SIL204 that we first reported in May,” said Ilan Hadar, Chairman and Chief Executive Officer of Silexion Therapeutics.

“In one integrated dataset, we are now seeing that SIL204 modulates three of the most important mechanisms by which KRAS-driven

tumors evade the immune system - upregulating antigen presentation via MHC-I, upregulating FAS to restore sensitivity to immune-mediated

cell death, and downregulating the HLA-G immune checkpoint to remove a key inhibitory signal to immune cells. SIL204 is producing this

coordinated immune-sensitizing effect across multiple KRAS mutations and both of the largest KRAS-driven tumor types. We believe this

profile supports the rationale for further evaluation of SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies, particularly

in indications like pancreatic cancer where these agents have historically shown limited single-agent efficacy.”

FAS (also known as CD95) is a cell surface death receptor whose engagement

by Fas ligand (FasL) - which is expressed on activated CD8+ T cells and natural killer (NK) cells - triggers programmed cell death of

the target cell. Cancer cells, and KRAS-driven tumors in particular, commonly downregulate FAS to evade immune-mediated killing. Recent

research published in Developmental Cell (Cell Press) has demonstrated that elimination of oncogenic KRAS in genetic mouse models of pancreatic

ductal adenocarcinoma restores FAS expression and enables FasL-expressing CD8+ T cells to eradicate KRAS-driven tumors.¹ In the newly

reported Silexion study, SIL204 treatment produced statistically significant, dose-dependent increases in FAS expression at 72 hours in

human KRAS G12D-mutant pancreatic cancer cells (PK59; up to approximately 2-fold, P<0.0001 vs. control) and in KRAS G12V-mutant NSCLC

cells (CORL23; P<0.05 vs. control).

HLA-G is a non-classical HLA class I molecule that functions as a potent

immune checkpoint. When expressed on tumor cells, HLA-G binds inhibitory receptors - including ILT-2 (LILRB1), ILT-4 (LILRB2), and KIR2DL4

- on CD8+ T cells, NK cells, and myeloid immune cells, suppressing their anti-tumor activity and enabling immune escape.² HLA-G is

a recognized and increasingly prominent drug target in oncology, with multiple HLA-G-directed programs currently in clinical development

in advanced solid tumors. In the newly reported study, SIL204 treatment produced statistically significant, dose-dependent reductions

in HLA-G expression in human KRAS G12C-mutant NSCLC cells (NCI-H358; P<0.001 at 24 hours and P<0.01 at 72 hours vs. control at the

200 nM dose), with additional reductions observed in KRAS G12D-mutant pancreatic and KRAS G12V-mutant NSCLC cells.

Taken together with the Company’s previously reported May 2026

findings demonstrating statistically significant upregulation of MHC-I (HLA-ABC) in KRAS G12R-mutant pancreatic cancer cells, these new

data support a coordinated immune-sensitization signature across three key immune pathways. The immune-modulatory effects have now been

observed across four distinct KRAS mutations (G12D, G12V, G12C, and G12R) in both pancreatic and non-small cell lung cancer models, reinforcing

the potential applicability of SIL204’s mechanism across the largest KRAS-driven cancer patient populations.

The findings arrive at a moment when the oncology field is actively

exploring combinations of KRAS-directed therapies with immune checkpoint inhibitors, with recent academic and industry work demonstrating

that combining KRAS inhibition with anti-PD-1 or anti-PD-L1 agents can produce sustained tumor regression and reprogramming of the tumor

microenvironment in KRAS-driven cancers.³ Pancreatic ductal adenocarcinoma and KRAS-mutant NSCLC together represent the largest KRAS-driven

patient populations, with KRAS mutations present in approximately 90% of pancreatic cancers and 30–35% of lung adenocarcinomas.

Immune checkpoint inhibitors have shown limited single-agent efficacy in pancreatic cancer and variable response rates in KRAS-mutant

NSCLC, driving substantial scientific and commercial interest in strategies capable of converting “immunologically cold” tumor

phenotypes into more immunotherapy-responsive tumors. The Company believes these findings provide additional translational support for

SIL204’s ongoing Phase 2/3 clinical development.

Image Caption: SIL204 treatment upregulates FAS and downregulates

HLA-G expression in human KRAS-mutant cancer cells. FAS expression at 72 hours (upper panel) in pancreatic (PK59, G12D) and NSCLC (CORL23,

G12V; NCI-H358, G12C)cells treated with SIL204, the Company's clinical KRAS-targeting siRNA. HLA-G expression at 24 hours (lower left)

and 72 hours (lower right) in the same cell lines. Gene expression quantified by qPCR, normalized to GAPDH and control samples using the

2^-ΔΔCt method. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs. control.

About Silexion Therapeutics

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused

biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have

the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a

Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy

alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3

clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further

developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements

regarding the therapeutic potential, immune-modulating activity, mechanism of action, translational significance including its potential

role in modulating antigen presentation, restoring immune recognition, reducing immune checkpoint activity, enhancing responsiveness to

checkpoint inhibitor therapies, and future immuno-oncology or combination applications, are forward-looking statements. These forward-looking

statements are generally identified by terminology such as “may”, “should”, “could”, “might”,

“plan”, “possible”, “expect”, “intend”, “will”, “estimate”, “anticipate”,

“believe”, “predict”, or “potential”, or the negatives of these terms or variations of them or similar

terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ

materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not

limited to: (i) the inherent uncertainties associated with preclinical research and drug development, including the risk that preclinical

findings may not translate to clinical outcomes; (ii) Silexion’s ability to successfully complete additional preclinical studies

and initiate and conduct clinical trials, including the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer; (iii) Silexion’s

strategy, future operations, financial position, projected costs, prospects, and plans; (iv) the impact of the regulatory environment

and compliance complexities, including site-level approvals, conditions and clearances required prior to study commencement at each clinical

site in Israel and Germany, and the timing and outcome of additional regulatory submissions and reviews in further EU member states, the

United States, and other jurisdictions; (v) expectations regarding future partnerships or other relationships with third parties; (vi)

Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vii) Silexion’s

ability to maintain its Nasdaq listing; and (viii) other risks and uncertainties set forth in the documents filed by the Company with

the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17,

2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 15, 2026.

Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information

currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the

date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances,

or changes in beliefs, except as otherwise required by law.

Company Contact

Silexion Therapeutics Corp

Ms. Mirit Horenshtein Hadar, CFO

mirit@silexion.com

Investor Relations Contact

Arx Investor Relations

North American Equities Desk

silexion@arxhq.com

____________________

¹ Mahadevan KK et al., Elimination of oncogenic KRAS in

genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells, Developmental Cell (2023).

² See Loustau M et al., HLA-G Neo-Expression on Tumors,

Frontiers in Immunology (2020); Lin A and Yan WH, Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges,

Frontiers in Immunology (2018).

³ See Mahadevan KK et al., KRASG12D inhibition reprograms

the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells, Cancer Cell (2023);

Kemp SB et al., Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer, Cancer

Discovery (2023); MD Anderson Cancer Center research on combination of KRAS G12D inhibition with checkpoint inhibitors in pancreatic

cancer models.

GRAPHIC

Filename: image_001.jpg · Sequence: 7

Binary file (2131 bytes)

Download image_001.jpg

GRAPHIC

Filename: image_002.jpg · Sequence: 8

Binary file (43114 bytes)

Download image_002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 10

v3.26.1

Cover

Apr. 28, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 04, 2026

Entity File Number

001-42253

Entity Registrant Name

Silexion Therapeutics

Corp

Entity Central Index Key

0002022416

Entity Tax Identification Number

00-0000000

Entity Incorporation, State or Country Code

Entity Address, Address Line One

12 Abba Hillel Road

Entity Address, City or Town

Ramat-Gan

Entity Address, Country

Entity Address, Postal Zip Code

5250606

City Area Code

+972

Local Phone Number

3-756-4999

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Ordinary Shares, par value $0.135 per share

Trading Symbol

SLXN

Security Exchange Name

NASDAQ

Warrants Exercisable For Ordinary Shares [Member]

Title of 12(b) Security

Warrants exercisable for Ordinary Shares at an exercise price of $15,525.00 per share

Trading Symbol

SLXNW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=SLXN_WarrantsExercisableForOrdinarySharesMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: